caa a22 4500 469116617 CHVBK 20180323133126.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF00172471 doi (NATIONALLICENCE)springer-10.1007/BF00172471 The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs [Elektronische Daten] [Sergi Obukhov, Martin Gennie, Alison Tutt, John Kemshead, Hugh Coakham, Peter Beverley] The ability of IL-2 stimulated mononuclear cells to kill the human glioblastoma cell line U251 has been investigated. Highest cytotoxic activity was generated in low cell density cultures incubated for 15 days with 250-1000 U/ml IL-2. Sub-optimal killing was noted, with cells only exposed to IL-2 for three days. Under the latter conditions, bispecific monoclonal antibodies (MoAbs) of either anti-CD3 or anti-CD16 and an anti-NCAM MoAb stimulated LAK cell activity markedly. Anti-CD16 conjugates were found more effective than anti-CD3 and (Fab′)2 constructs more efficacious than those made with whole Ig molecules. Maximal stimulation of LAK cell activity was noted with bispecific MoAbs. Little effect was observed with either single or mixtures of monomeric MoAbs. Furthermore, no effect of bispecific MoAbs was observed when target cells lacked expression of NCAM. These results could be of clinical importance as it is not always feasible to screen LAK cells for optimal activity before administration to patients. Whilst bispecific MoAbs have no effect on optimally stimulated LAK cells, they are not inhibitory and can stimulate killing under sub-optimal IL-2 stimulation. Kluwer Academic Publishers, 1992 Bispecific monoclonal antibody (MoAb) nationallicence LAK cells nationallicence glioma nationallicence NCAM nationallicence CD3 nationallicence CD16 nationallicence Obukhov Sergi Burdenko Neurosurgical Institute, Moscow, USSR aut Gennie Martin Tenovus Research Institute, Southampton General Hospital, Southampton, UK aut Tutt Alison Tenovus Research Institute, Southampton General Hospital, Southampton, UK aut Kemshead John Imperial Cancer Research Fund, Paediatric & Neuro-Oncology Group, Frenchay Hospital, Bristol, UK aut Coakham Hugh Imperial Cancer Research Fund, Paediatric & Neuro-Oncology Group, Frenchay Hospital, Bristol, UK aut Beverley Peter Imperial Cancer Research Fund, Human Tumour Immunology Group, Middlesex Hospital, London, UK aut Journal of Neuro-Oncology Kluwer Academic Publishers 13/3(1992-07-01), 203-210 0167-594X 13:3<203 1992 13 11060 https://doi.org/10.1007/BF00172471 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172471 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Obukhov Sergi Burdenko Neurosurgical Institute, Moscow, USSR aut NATIONALLICENCE 700 1- Gennie Martin Tenovus Research Institute, Southampton General Hospital, Southampton, UK aut NATIONALLICENCE 700 1- Tutt Alison Tenovus Research Institute, Southampton General Hospital, Southampton, UK aut NATIONALLICENCE 700 1- Kemshead John Imperial Cancer Research Fund, Paediatric & Neuro-Oncology Group, Frenchay Hospital, Bristol, UK aut NATIONALLICENCE 700 1- Coakham Hugh Imperial Cancer Research Fund, Paediatric & Neuro-Oncology Group, Frenchay Hospital, Bristol, UK aut NATIONALLICENCE 700 1- Beverley Peter Imperial Cancer Research Fund, Human Tumour Immunology Group, Middlesex Hospital, London, UK aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 13/3(1992-07-01), 203-210 0167-594X 13:3<203 1992 13 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer